Archives
-
β-Elemene Inhibits 3T3-L1 Adipogenesis via AMPK
2026-09-09
The reference study identifies β-Elemene as an inhibitor of MDI-induced adipogenesis and a regulator of insulin-resistance phenotypes in differentiated 3T3-L1 cells. Its central contribution is linking reduced lipid accumulation and restored glucose consumption with recovery of AMPK signaling, while also defining a practical in vitro workflow for metabolic research.
-
DiscoveryProbe Protease Inhibitor Library Workflow
2026-09-08
Build mechanism-aware protease screens around 825 pre-dissolved inhibitors, from cell-based AlphaLISA to apoptosis and high-content phenotyping. This workflow emphasizes controls, orthogonal validation, resistance testing, and practical troubleshooting rather than treating every inhibitor as a generic hit.
-
TSA and the Next Generation of Organoid Epigenetics
2026-09-08
Trichostatin A (TSA) offers a reversible way to connect HDAC activity with chromatin state, proliferation, and differentiation. This article positions TSA within a more advanced translational framework inspired by a tunable human intestinal organoid system, moving beyond simple potency testing toward controlled, mechanism-led model design.
-
Tyrothricin in Membrane-Disruption Workflows
2026-09-07
Tyrothricin is a peptide antibiotic mixture that enables controlled studies of microbial membrane injury, while demanding careful separation of antimicrobial activity from mammalian-cell toxicity. This workflow guide connects membrane assays with mitochondrial-transfer and inflammatory-pain models, offering practical controls, optimization points, and troubleshooting strategies.
-
(-)-Epigallocatechin Gallate (EGCG): Evidence Guide
2026-09-07
(-)-Epigallocatechin gallate (EGCG) is a major green tea catechin studied for antioxidant, apoptosis, antiangiogenic, antiviral, and cancer chemoprevention applications. In a three-dimensional calcium phosphate scaffold, EGCG supported osteogenic markers, reduced osteoclastogenic RANKL expression, affected endothelial tube formation, and reduced osteosarcoma-cell viability under defined in vitro conditions.
-
TMEM16F Lipid Scrambling in Ferroptosis and Immunity
2026-09-05
Yang and colleagues identify TMEM16F-mediated phospholipid scrambling as a membrane-protective checkpoint during the executional phase of ferroptosis. Loss of this activity promotes plasma-membrane collapse, danger-signal release, slower tumor growth, and stronger responses to PD-1 blockade, providing a mechanistic link between lipid organization and antitumor immunity.
-
PCI-32765 (Ibrutinib) for BTK Research
2026-09-04
Build more interpretable B-cell experiments with PCI-32765, an irreversible BTK inhibitor suited to B-cell receptor signaling inhibition, CLL viability studies, and activation assays. This workflow combines target-focused perturbation with orthogonal controls, pulse-washout testing, and lessons from a multi-condition disease-modeling study.
-
Z-WEHD-FMK as a Pyroptosis Causality Probe
2026-09-04
Z-WEHD-FMK enables mechanistic testing of inflammatory caspase activity across pyroptosis, cancer biology, and infection models. This article explains how to use it as a causality probe while avoiding the common error of treating inhibitor rescue as pathway proof.
-
Simvastatin: High-Content Research Workflows
2026-09-03
Simvastatin (Zocor) links cholesterol-pathway perturbation with practical phenotypic profiling in lipid and cancer models. This workflow-oriented guide covers stock preparation, hepatic apoptosis assays, cross-cell-line machine learning, and troubleshooting for reproducible research.
-
Ruxolitinib–oHSV Therapy Reprograms Sarcoma Immunity
2026-09-03
The reference study introduces a 46-color spectral flow cytometry panel to resolve lymphoid and myeloid immune changes after combined Ruxolitinib and oncolytic herpes simplex virus treatment in murine malignant peripheral nerve sheath tumors. The combination was associated with activated germinal center B cells and cytokine-producing CD4 T-cell states, expanding interpretation beyond conventional cytotoxic T-cell and regulatory T-cell analyses.
-
ORM2, ZG16, and Autophagy in Pancreatic Fibrosis
2026-09-02
The reference study identifies ORM2 as an endogenous suppressor of chronic pancreatitis-associated fibrosis and places ZG16 at the center of its mechanism. Using mouse and pancreatic stellate cell models, the authors show that ORM2 limits autophagy-driven stellate cell activation by preventing autolysosome formation, providing a mechanistic framework for antifibrotic research.
-
Imipenem Workflows for Resistance Research
2026-09-02
Imipenem supports more than routine susceptibility testing: it can anchor integrated workflows connecting PBP-directed antibacterial activity, carbapenemase transmission, and carefully controlled immune assays. This guide translates resistance-surveillance findings into practical assay design, optimization, and troubleshooting choices.
-
Demethyleneberberine: Mechanisms and Research Use
2026-09-01
Demethyleneberberine (DMB) is a berberine metabolite and natural isoquinoline alkaloid investigated across inflammation, neurodegeneration, autoimmune hepatitis, and non-small cell lung cancer research. Product-dossier data support defined in vitro and in vivo starting ranges, while the Huntington’s disease application remains a mechanistic hypothesis rather than a clinical efficacy claim.
-
U0126 for Reproducible MEK1/2 Assays
2026-09-01
This scenario-driven guide explains how U0126, SKU BA2003, can strengthen cell viability, proliferation, and cytotoxicity workflows by separating MEK1/2–ERK signaling effects from nonspecific metabolic changes. It covers mechanism, controls, stock preparation, pathway validation, cross-domain interpretation, and practical product selection.
-
Localized Muscle BDNF in Early NMJ Formation
2026-08-31
This study shows that skeletal muscle-derived BDNF is transported to podosome-like structures, where activity-dependent release and proteolytic processing support the earliest stages of neuromuscular junction development. Combining live-cell imaging, molecular perturbation, agrin- and nerve-induced clustering assays, and muscle-specific BDNF knockout mice, the work connects spatial neurotrophin signaling with acetylcholine receptor organization.